Screening for Breast Cancer

Author:

,Nicholson Wanda K.1,Silverstein Michael2,Wong John B.3,Barry Michael J.4,Chelmow David5,Coker Tumaini Rucker6,Davis Esa M.7,Jaén Carlos Roberto8,Krousel-Wood Marie9,Lee Sei10,Li Li11,Mangione Carol M.12,Rao Goutham13,Ruiz John M.14,Stevermer James J.15,Tsevat Joel8,Underwood Sandra Millon16,Wiehe Sarah17

Affiliation:

1. George Washington University, Washington, DC

2. Brown University, Providence, Rhode Island

3. Tufts University School of Medicine, Boston, Massachusetts

4. Harvard Medical School, Boston, Massachusetts

5. Virginia Commonwealth University, Richmond

6. University of Washington, Seattle

7. University of Maryland School of Medicine, Baltimore

8. The University of Texas Health Science Center, San Antonio

9. Tulane University, New Orleans, Louisiana

10. University of California, San Francisco

11. University of Virginia, Charlottesville

12. University of California, Los Angeles

13. Case Western Reserve University, Cleveland, Ohio

14. University of Arizona, Tucson

15. University of Missouri, Columbia

16. University of Wisconsin, Milwaukee

17. Indiana University, Bloomington

Abstract

ImportanceAmong all US women, breast cancer is the second most common cancer and the second most common cause of cancer death. In 2023, an estimated 43 170 women died of breast cancer. Non-Hispanic White women have the highest incidence of breast cancer and non-Hispanic Black women have the highest mortality rate.ObjectiveThe USPSTF commissioned a systematic review to evaluate the comparative effectiveness of different mammography-based breast cancer screening strategies by age to start and stop screening, screening interval, modality, use of supplemental imaging, or personalization of screening for breast cancer on the incidence of and progression to advanced breast cancer, breast cancer morbidity, and breast cancer–specific or all-cause mortality, and collaborative modeling studies to complement the evidence from the review.PopulationCisgender women and all other persons assigned female at birth aged 40 years or older at average risk of breast cancer.Evidence AssessmentThe USPSTF concludes with moderate certainty that biennial screening mammography in women aged 40 to 74 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening mammography in women 75 years or older and the balance of benefits and harms of supplemental screening for breast cancer with breast ultrasound or magnetic resonance imaging (MRI), regardless of breast density.RecommendationThe USPSTF recommends biennial screening mammography for women aged 40 to 74 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women 75 years or older. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of supplemental screening for breast cancer using breast ultrasonography or MRI in women identified to have dense breasts on an otherwise negative screening mammogram. (I statement)

Publisher

American Medical Association (AMA)

Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3